Brean Capital


Brean Capital Chimes in on Neuralstem, Inc. (CUR) Following Agreement with Tianjin Pharmaceutical

Neuralstem, Inc. (NASDAQ:CUR) shares are climbing nearly 6% after announcing this morning it had entered into an official agreement with Tianjin Pharmaceutical Holding Group, …

Brean Capital Take on Vanda Pharmaceuticals Inc.’s (VNDA) Patent Win; Raises Price Target to $24

Brean Capital analyst Difei Yang was out today with a few insights on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), following the news that the U.

Brean Capital Downgrades Medivation Inc (MDVN) in Wake of Pfizer Merger Agreement

Pfizer will acquire Medivation for $81.50 per share in cash- an offer unlikely to be bested, says Brean Capital

Brean Capital Sees Newest Nike Inc (NKE) Partnership as Long-Term Game Changer

Brean Capital thinks Nike’s strategic supply chain partnership will become an important trend in meeting consumer demand

Top Analyst Lifts Price Target on Micron Technology, Inc. (MU) Following Flash Memory Summit

Brean Capital analyst Mike Burton was out raising the price target for Micron Technology, Inc. (NASDAQ:MU) to $18 (from $14), after the chip giant presented …

This Top Analyst Remains on the Sidelines with NVIDIA Corporation (NVDA); Here’s Why

NVIDIA Corporation (NASDAQ:NVDA) released its fiscal 2017 second quarter results yesterday, which surpassed Street expectations, primarily driven by by strong Pascal GPU demand and rapid growth …

Brean Capital Slashes Price Target for Neuralstem, Inc. (CUR) to Reflect More Conservative Stance

In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), while slashing the …

Brean Capital Heads to Sidelines on Pernix Therapeutics Holdings Inc (PTX); Here’s Why

In a research report issued Friday, Brean Capital analyst Difei Yang downgraded shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) from Buy to Hold, after the pharma …

Brean Capital Weighs In On Heron Therapeutics Inc (HRTX) Following FDA Approval For Sustol

In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …

Brean Capital Analyst Bullish on Inovio Pharmacueticals Inc (INO) Amid 2Q:16 Update

In a research note issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) with a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts